Kevin Hern | Vice President-Investor Relations |
Dave Ricks | Lilly's Chairman and Chief Executive Officer |
Josh Smiley | Chief Financial Officer |
Dan Skovronsky | President-Lilly Research Laboratories |
Anne White | President-Lilly Oncology |
Enrique Conterno | President-Lilly Diabetes and Lilly U.S.A |
Umer Raffat | Evercore |
Terence Flynn | Goldman Sachs |
Andrew Baum | Citi |
Steve Scala | Cowen |
David Risinger | Morgan Stanley |
Seamus Fernandez | Guggenheim |
Chris Schott | JPMorgan |
Tim Anderson | Wolfe Research |
Louise Chen | Cantor Fitzgerald |
Jason Gerberry | Bank of America |
Navin Jacob | UBS |
Ladies and gentlemen, thank you for standing by and welcome to the quarter two 2019 earnings call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Kevin Hern, Vice President of Investor Relations. Please go ahead.
Good morning.